The vaccine was found to be about 27% more effective than the standard flu shot in a late-stage trial. The FDA and the CDC still must sign off on the vaccine before it’s available.

Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this…

Moderna's novel vaccine was at the center of dustup with agency earlier this year

U.S. health advisers are debating a new kind of flu vaccine

Recommendation could pave the way for approval of the mRNA vaccine in adults 50 and up

In February, a Trump official refused to review the vaccine.